Acadia Pharmaceuticals opened lower at $18.22, compared with its previous close of $18.37. In the last trading session, the stock traded between $18.00 and $18.37. It showed a downward intraday trend.
An investment of $100 made 5 years ago in Acadia Pharmaceuticals is now worth
$ 87.70
Resulting in a loss of
$ 12.30 (12.30%)
Note: Past profits do not guarantee future returns.
Rating from 13 Analysts
Today's Change
$-0.23 (-1.27%)
Day High
$18.37
Day Low
$18.00
Day Open
$18.22
Prev Close
$18.37
Volume
14,53,814
1W Return
-15.61%
1M Return
-6.54%
3M Return
-38.32%
6M Return
-16.80%
1Y Return
-23.54%
Market Cap ($ Mn)
3,135
PE Ratio
13.06
PB Ratio
3.84
PEG Ratio
0.19
ROE
43.78%
ROCE
11.21%
EPS (TTM)
$0.31
1 Week
-15.61%
1 Month
-6.54%
3 Months
-38.32%
6 Months
-16.80%
9 Months
-19.28%
Acadia Pharmaceuticals to report Q3FY26 results on November 4
Acadia Pharmaceuticals will announce Q3 2026 results on November 4, 2026. Conference call scheduled for 4:30 pm ET after market close. Webcast available on acadia.com with 90-day archive. Portfolio includes treatments for Parkinson's disease psychosis and Rett syndrome.
22 days agoPomerantz investigates Acadia Pharmaceuticals after trial miss
Pomerantz LLP is investigating ACADIA Pharmaceuticals for potential securities fraud. Stock fell 12.78% on September 24, 2026, after remlifanserin missed a primary endpoint. Shares declined another 6.76% on September 25, 2026, following analyst downgrades. Investigation focuses on disclosures regarding the RADIANT clinical trial program.
1mo agoPomerantz probes Acadia over ADP trial data disclosure
Pomerantz LLP investigates Acadia Pharmaceuticals for potential securities fraud. Stock fell 12.78% to $22.18 after Phase 2 remlifanserin missed primary endpoint. Deutsche Bank cuts price target to $31; Needham lowers target to $35. Secondary endpoint CGI-S-ADP showed statistical significance with p=0.0077.
1mo agoAcadia Pharmaceuticals secures US patent for Rett syndrome drug
Acadia Pharmaceuticals received a USPTO notice of allowance for a patent covering Trofinetide. The patent extends U.S. market protection for the Rett syndrome drug until March 2041. The allowed application covers weight-banded dosing methods and compositions.
1mo agoAcadia Pharmaceuticals secures EU approval for DAYBU in Rett syndrome
European Commission approves DAYBU (trofinetide) for Rett syndrome in EU. First and only authorized treatment for the condition in the region. Approval covers 27 EU member states plus Iceland, Liechtenstein, Norway. Based on Phase 3 LAVENDER study showing significant clinical improvements.
2mo agoAcadia Pharmaceuticals to Participate in Canaccord Genuity 46th Annual Growth Conference
Acadia Pharmaceuticals Inc. will participate in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026, at 1:30 p.m. Eastern Time. A live webcast will be available through the investors section of acadia.com, with an archived recording accessible for approximately one month after the event. The company holds FDA-approved treatments for Parkinson's disease psychosis and Rett syndrome, and maintains a pipeline with mid- to late-stage programs in Alzheimer's disease psychosis and Lewy body dementia psychosis.
3mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $547.03 | -0.16% | $1,38,692.89M | 31.55 | |
| $61.05 | +0.38% | $1,31,510.31M | 14.39 | |
| $248.69 | -0.85% | $1,00,625.20M | - | |
| $959.41 | +4.73% | $97,505.80M | 19.64 | |
| $977.58 | +0.62% | $61,476.10M | 38.99 | |
| $419.98 | -0.95% | $46,108.31M | 65.60 | |
| $180.70 | -6.40% | $39,083.96M | - | |
| $53.87 | -0.37% | $33,618.11M | 26.24 | |
| $70.01 | +0.81% | $31,173.07M | 32.37 | |
| $41.85 | +1.60% | $30,322.88M | - | |
| $120.75 | +1.05% | $26,490.14M | - | |
| $122.27 | +1.64% | $24,922.54M | 15.85 |
An investment of $100 made 5 years ago in Acadia Pharmaceuticals is now worth
$ 87.70
Resulting in a loss of
$ 12.30 (12.30%)
Note: Past profits do not guarantee future returns.
